NCT01082172CompletedNot Applicable
A Pilot Trial to Evaluate the Performance of the TriVascular Thoracic Stent Graft System
Conditions
Interventions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- TriVascular, Inc.
- Enrollment
- 2
- Locations
- 1
- Primary Endpoint
- Absence of device-related serious adverse events within 30-days of endovascular procedure
Study Overview
Brief Summary
A prospective, non-randomized multi-center clinical evaluation of the performance of the TriVascular Thoracic Stent Graft System when used in the treatment of subjects with thoracic aortic aneurysms (TAA).
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •The TriVascular Thoracic Stent Graft System is indicated in subjects diagnosed with an aneurysm in the descending thoracic aorta having vascular morphology suitable for endovascular repair, including:
- •Adequate iliac/femoral access compatible with the required delivery systems,
- •Non-aneurysmal aortic segments proximal and distal to the aneurysm.
Exclusion Criteria
- Not provided
Arms & Interventions
Thoracic Stent Graft
Experimental
Thoracic Stent Graft implanted device
Intervention: Implant Thoracic Stent Graft (Device)
Outcomes
Primary Outcomes
Absence of device-related serious adverse events within 30-days of endovascular procedure
Time Frame: 30-Days
Secondary Outcomes
No secondary outcomes reported
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Not yet recruiting
Not Applicable
A prospective multi-center randomized clinical trial to compare survival rates and to observe quality of life and nutritional status according to follow-up period in patients who underwent radical gastrectomy for advanced gastric cancerNeoplasmsKCT0006547ational Cancer Center886
Completed
Not Applicable
An Observational, Prospective Evaluation of the Trifecta™ ValveRegurgitation, Aortic ValveAortic Valve IncompetenceAortic Valve InsufficiencyAortic Valve StenosisNCT00727181Abbott Medical Devices120
Completed
Phase 4
A prospective, multicentre study to see the safety of Osimertinib in Indian adult patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive nonsmall cell lung cancer.CTRI/2018/10/015941AstraZeneca Pharma India Limited60
Active, not recruiting
Phase 4
Study to check safety of Durvalumab in Indian patients with non-small cell lung cancerCTRI/2020/08/027287AstraZeneca Pharma India Ltd
Active, not recruiting
Not Applicable
REDUCED 1 - Renal Denervation Using Ultrasonic Catheter EmitteD Energy Study /Uncontrolled Stage 2 HypertensionNCT05372679SoniVie Inc.25